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The aim of this study is to define the maximum tolerated dose (MTD), safety, pharmacokinetics (PKs) and efficacy of ispinesib
(SB-715992) in combination with docetaxel. Patients with advanced solid tumours were treated with ispinesib (6–12mgm
 2) and
docetaxel (50–75mgm
 2). Docetaxel was administered over 1h followed by a 1-h infusion of ispinesib on day 1 of a 21-day
schedule. At least three patients were treated at each dose level. Blood samples were collected during cycle 1 for PK analysis. Clinical
response assessments were performed every two cycles using RECIST guidelines. Twenty-four patients were treated at four dose
levels. Prolonged neutropaenia and febrile neutropaenia were dose limiting in six and two patients, respectively. The MTD was
ispinesib 10mgm
 2 with docetaxel 60mgm
 2. Pharmacokinetic assessment demonstrated concentrations of ispinesib and
docetaxel, consistent with published data from single agent studies of the drugs. Seven patients (six hormone refractory prostate
cancer (HRPC), one renal cancer) had a best response of stable disease (X18 weeks). One patient with HRPC had a confirmed
450% prostatic-specific antigen decrease. The MTD for ispinesib and docetaxel was defined and the combination demonstrated an
acceptable toxicity profile. Preliminary PK data suggest no interaction between ispinesib and docetaxel.
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Mitotic kinesins are a subset of the kinesin enzyme super family,
and they are involved in the establishment and function of the
mitotic spindle as well as cell cycle progression (Wood et al, 2001).
In contrast to tubulin, mitotic kinesins are preferentially expressed
in proliferating cells, with specific activity during mitosis, and are
thus an attractive molecular target for anticancer therapy
(Sakowicz et al, 2004). Kinesin spindle protein (KSP, Eg5,
kinesin-5) provides the propulsive forces required to separate
centrosomes during prophase, enabling them to migrate to
opposite poles and establish a functional bipolar spindle (Blangy
et al, 1995). Kinesin spindle protein is greatly expressed in
proliferating over non-proliferating cells and in tumour tissue
relative to normal tissue (Hegde et al, 2003). In in vitro
experiments, cells treated with the prototype KSP inhibitor,
monastrol, displayed abnormal, monopolar spindles with chromo-
somes attached via microtubules to a single pole, resulting in
deranged cell division, mitotic cell cycle arrest and apoptosis
(Mayer et al, 1999; Cochran et al, 2005).
Ispinesib (SB-715992), a potent and selective small molecule
inhibitor of KSP, functions by inhibiting KSP ATPase and is 40000
times more selective for KSP compared to other kinesins (Johnson
et al, 2002). In preclinical studies, ispinesib inhibited growth in a
wide range of human and murine cell lines with IC50 values of
1.2–9.5nM. Treatment of SKOV3 ovarian tumour cells in vitro with
20nM of ispinesib, or a Colo 205 colon cancer murine xenograft
model with 30mgkg
 1 of intraperitoneal ispinesib, caused mitotic
arrest with cells demonstrating unseparated centrosomes and
monopolar mitotic spindles. Tumour growth delay was observed in
xenograft models of colon (HT29, Colo201, Colo205), non-small
cell lung (Calu-3) and pancreatic (Panc-01) cancers.
Phase I studies have evaluated three schedules of ispinesib
administered on days 1–3 every 21 days, day 1 every 21 days and
days 1, 8 and 15 every 28 days (Chu et al, 2003, 2004; Burris et al,
2004). In all studies, the dose-limiting toxicity (DLT) was
prolonged neutropaenia or febrile neutropaenia. Other toxicities
were mild with no significant neurotoxicity observed. Phase II
studies are either ongoing or have been completed in multiple
tumour types (Miller et al, 2005; Shahin et al, 2007).
A 9% objective response rate was observed in patients with
metastatic breast cancer who had relapsed or were refractory to
prior anthracycline and taxane therapy (Miller et al, 2005).
Ispinesib has been evaluated in combination with both carboplatin
and capecitabine in two phase I studies of 28 and 24 patients,
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has been reported (Jones et al, 2006; Rodon et al, 2006).
This phase I study combines ispinesib with docetaxel. Docetaxel,
a member of the taxane family, has activity in breast cancer, non-
small cell lung cancer (NSCLC) and hormone refractory prostate
cancer (HRPC) (Chan et al, 1999; Nabholtz et al, 1999; Fossella
et al, 2000, 2003; Shepherd et al, 2000; Tannock et al, 2004). It is
currently approved in several indications:
(i) As second-line monotherapy for locally advanced or meta-
static breast cancer (Taxotere
s, 2005).
(ii) In combination with doxorubicin and cyclophosphamide for
the adjuvant treatment of node-positive early breast cancer
(Taxotere
s, 2005).
(iii) In locally advanced or metastatic NSCLC as first-line therapy
in combination with cisplatin or as second-line monotherapy.
(iv) In advanced gastric and gastro-oesophageal junction adeno-
carcinoma, it is approved as first-line therapy in combination
with cisplatin and fluorouracil.
(v) In squamous cell carcinoma of the head and neck as
induction treatment for inoperable locally advanced disease
with cisplatin and fluorouracil.
(vi) In combination with prednisone for patients with HRPC
(Taxotere
s, 2005).
Docetaxel binds reversibly to the beta subunit of tubulin,
promoting microtubule assembly and stability, thereby blocking
the cell cycle in mitosis (Eisenhauer and Vermorken, 1998).
Myelosuppression is the DLT of docetaxel and occurs in 475% of
patients treated with 60mgm
 2 (Taxotere
s, 2005). Peripheral
sensory neuropathy is another prominent toxicity, thought to
occur as a result of tubulin stabilisation disrupting the architecture
of non-dividing neuronal cells. Both docetaxel and ispinesib can
induce mitotic arrest and apoptotic cell death; however, in the
MX-1 tumour mouse xenograft model, preclinical data demon-
strated synergy when both agents were used concurrently (data on
file at GlaxoSmithKline).
The primary objectives of this study were to determine the safety
and MTDs of ispinesib and docetaxel in combination. Secondary
objectives were to define the pharmacokinetic (PK) profiles of both
agents and their efficacy.
MATERIALS AND METHODS
Eligible patients were recruited from The Royal Marsden Hospital,
Sutton, and the Churchill Hospital, Oxford. GlaxoSmithKline
sponsored the study. The study obtained full ethical approval
and was conducted in accordance with ICH-GCP guidelines.
Patient eligibility
Patients with histologically confirmed locally advanced or meta-
static solid tumours, refractory to conventional therapy or for
which no standard therapy exists, were eligible provided they met
the following criteria: age X18; Eastern Co-operative Oncology
Group (ECOG) performance status (PS) 0–1; life expectancy of
X12 weeks; adequate haematopoietic (absolute neutrophil count
(ANC) X1.5 10
9l
 1, platelet count X100 10
9l
 1, haemoglobin
X9gdl
 1), hepatic (transaminases o2  upper limit of normal
(ULN) or o1.5  ULN if alkaline phosphatase X3  ULN,
bilirubin pULN) and renal function (creatinine clearance
440mlmin
 1 (calculated by the Cockroft–Gault Formula))
(Drinka and Langer, 1989); and a negative pregnancy test for
females of child-bearing potential.
Exclusion criteria included the following: pre-existing neuro-
pathy Xgrade 2; unstable or pre-existing major medical condi-
tions; evidence of symptomatic or uncontrolled brain metastases
or leptomeningeal disease; major surgery or any anticancer
therapy within the previous 4 weeks; lactating females; and
unwillingness to use barrier contraception throughout the trial.
Screening and study procedures
A full medical history and physical examination including PS,
baseline symptoms, adverse events, vital sign assessment, haema-
tology, coagulation and clinical chemistry were performed at
baseline and prior to each treatment. A pregnancy test for females
was performed prior to study entry only. Twelve-lead electro-
cardiograms were performed at baseline, prior to cycle 1 and
immediately following the end of ispinesib infusion on day 1, cycle
1. Clinical chemistry, haematology and adverse event assessments
were performed at days 8 and 15 of each cycle. Tumour assessment
by computed tomography or magnetic resonance imaging, as
defined by the RECIST guidelines (Therasse et al, 2000), was
performed within 21 days prior to first treatment and every two
cycles thereafter until discontinuation from the study. Patients
were withdrawn from the study in the event of progressive disease
(PD), unacceptable toxicity, withdrawal of consent or at the
physician’s discretion.
Drug administration
Ispinesib was supplied by GlaxoSmithKline as a clear colourless
solution in 4, 5 or 10ml vials containing a 1mgml
 1 solution of
drug. Docetaxel (Taxotere
s Sanofi-Aventis) was diluted as per the
prescribing information.
All patients were premedicated with dexamethasone 8mg p.o.
b.i.d. for 3 days starting at day 0. On day 1, docetaxel was first
administered as a 1h i.v. infusion, followed by ispinesib, in 250ml
of 5% glucose administered i.v. over 1h. The regimen was repeated
every 21 days. Post-treatment anti-emetics comprised of domper-
idone 20mg p.o. q.d.s.
Dose escalation, definition of DLT and MTD
The starting dose of ispinesib was 8mgm
 2 (Chu et al, 2004). The
starting dose of docetaxel was 60mgm
 2, selected on the basis of
the anticipated myelotoxic profile of the combination. The planned
dose escalation schedule is shown in Table 1.
Patients were treated in cohorts of three. In the absence of DLT,
dose escalation continued in successive cohorts of three patients
when three patients at the preceding dose level had completed a
21-day cycle. If one of the three patients experienced a DLT, an
additional three patients were recruited to the same dose level. If
no further DLTs were observed, dose escalation proceeded. If a
second DLT was seen in the cohort of six, the MTD was exceeded
and the dose below this was determined as the MTD.
Table 1 Planned dose escalation schema of ispinesib and docetaxel
Dose per 3 weekly cycle
Cohort/dose level Ispinesib Docetaxel
 26 m g m
 2 50mgm
 2
 16 m g m
 2 60mgm
 2
08 m g m
 2 60mgm
 2
A1 0 m g m
 2 60mgm
 2
+1 8mgm
 2 75mgm
 2
A1 0 m g m
 2 75mgm
 2
+2 12mgm
 2 75mgm
 2
+3 15mgm
 2 75mgm
 2
+4 18mgm
 2 75mgm
 2
Text in bold indicates the starting dose. Text in italics indicates alternative dose levels
that were planned if clarification of the MTD was required.
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Institute Common Terminology Criteria for Adverse Events
Version 3.0 (NCI-CTCAE v 3.0). Dose-limiting toxicity was defined
as any of the following: Xgrade 3 clinically significant non-
haematological toxicity (excluding Xgrade 3 nausea, vomiting or
alopaecia), Xgrade 3 nausea/vomiting/diarrhoea uncontrolled by
aggressive therapy, grade 4 neutropaenia lasting X5 days, grade 3
or 4 neutropaenia with fever X38.51C or infection, grade 4
thrombocytopaenia, inability to commence next cycle of treatment
within 2 weeks of scheduled dosing due to an unresolved toxicity
such that the original eligibility criteria were no longer met, grade
2 toxicity, which is considered a DLT by the investigator, Xgrade 2
non-haematological toxicity that persisted beyond cycle 1 and was
considered a DLT by the investigator.
Dose modification
Each new cycle of treatment was administered only if the following
criteria were met: ANC 41.5 10
9l
 1, platelet count
4100 10
9l
 1 and recovery from all clinically significant,
non-haematological toxicity (apart from alopaecia) to pgrade 1.
Treatment could be delayed for up to 2 weeks to allow these
criteria to be met, otherwise treatment was discontinued.
In the case of DLT, on recovery to re-treatment criteria, the
doses of both ispinesib and docetaxel were reduced 1 dose level for
the subsequent cycle (Table 1). In the case of grade 2 neuropathy,
treatment was withheld until resolved to grade 1 and the dose of
docetaxel alone was reduced by 1 dose level. Colony-stimulating
factors were prohibited during cycle 1 of treatment, but could be
used in cases of febrile neutropaenia in subsequent cycles.
Pharmacokinetic sampling
Plasma PK sampling was carried out on day 1 of cycle 1. A 4ml
blood sample was taken at the following time points relative to the
docetaxel infusion: prior to and 1, 2, 4–6 and 24h after the end of
docetaxel infusion. Further sampling for a pPK interaction was to
be performed at the MTD, if this was found to be less than dose
level þ3 (Table 1).
Ispinesib and docetaxel were extracted from plasma samples and
then analysed by HPLC-MS/MS using a TurboIonSprayt interface
and multiple reaction monitoring by the GlaxoSmithKline Division
of Drug Metabolism and Pharmacokinetics.
RESULTS
Twenty-four patients (21 male, 3 female), with a median age of 61.2
years, were treated between June 2004 and June 2005 (Table 2). A
wide range of tumour types was treated, with the most common
tumour type being HRPC.
Dose-limiting toxicities
Table 3 summarises the number of patients treated, cycles
administered and DLTs per dose level. Patients received a median
of three cycles of treatment (range 1–10). Six patients received six
or more cycles of treatment and 18 discontinued treatment
prematurely due to PD (12), adverse events (4), physician choice
(1) and patient choice (1). At dose level 0 (ispinesib 8mgm
 2 and
docetaxel 60mgm
 2), a patient with HRPC experienced a DLT of
prolonged grade 4 neutropaenia during course 1. The cohort was
thus expanded to six patients. There were no further DLTs.
At8mgm
 2 ispinesib and docetaxel 75mgm
 2, after an initial
patient with colorectal adenocarcinoma experienced a DLT of
prolonged grade 4 neutropaenia, the cohort was expanded to a
total of six patients. The second patient experienced prolonged
grade 4 neutropaenia with fever. In order to further clarify the
MTD, dose level A, at 10mgm
 2 ispinesib and docetaxel
60mgm
 2, was evaluated. There were no DLTs in the three
patients treated at this dose level. In view of recurrent prolonged
neutropaenia, we modified the dose escalation procedure to
Table 2 Patient characteristics
Number of patients 24
Median age, years (range) 61.2 (41–76)
Gender, M/F 21/3
Race
White 24
ECOG PS
09
11 4
Unknown 1
Tumour type
Prostate
a 14
Duodenal adenocarcinoma 2
Cervix 2
Bladder 1
Renal
b 2
Colon 1
Melanoma 1
Esophageal 1
Previous treatment
Chemotherapy 8
Median number of previous chemotherapy regimens (range) 1.5 (1–3)
Radiotherapy 10
Surgery 9
Biological therapy 2
ECOG¼Eastern Cooperative Group; F¼female; M¼male; PS¼performance
status
aAll chemonaive.
bPrevious immunotherapy.
Table 3 Dose levels, number of cycles administered and dose-limiting toxicities
Dose (mgm
 2)
Dose level Ispinesib Docetaxel n No. of cycles DLT
0 8 60 6 20 1 – prolonged grade 4 neutropaenia
+1 8 75 6 26 2 – prolonged grade 4 neutropaenia
and febrile neutropaenia
A 10 60 3 12 0
A1 12 60 6 25 3
a – prolonged grade 4 neutropaenia
Ae 10 60 3 16 0
A¼alternative dose level; Ae¼expansion of cohort A at MTD; n¼number of patients; No.¼number.
aX2 DLTs in cohort due to simultaneous enrolment of patients.
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 2 and increase the dose
of ispinesib only.
In cohort A1, ispinesib was administered at 12mgm
 2 and
docetaxel at 60mgm
 2. After a patient with renal carcinoma
developed prolonged grade 4 neutropaenia, the cohort was
expanded to six patients. A further two patients – one with
duodenal carcinoma and a second with squamous cell carcinoma
of the cervix – experienced prolonged grade 4 neutropaenia. With
three out of six patients at this dose level experiencing DLT, the
MTD was defined as ispinesib 10mgm
 2 and docetaxel 60mgm
 2.
The MTD cohort was expanded by a further three patients with no
further DLTs.
Haematological toxicity
All patients were evaluable for toxicity. Table 4 summarises drug-
related haematological toxicities experienced by patients; the most
common was neutropaenia in 83% (n¼20) patients. Eighteen of
the twenty-four (75%) patients experienced grade 3 or 4
neutropaenia, and in six of these, prolonged grade 4 neutropaenia
constituted a DLT. Four patients developed febrile neutropaenia.
Anaemia was significant (grade 3 or 4) in three patients. Grade 4
thrombocytopaenia was seen in one patient that was due to an
idiopathic immune thrombocytopaenic purpura, with no clear
relationship to study drug; the patient was on concomitant
medication (quinine) that could have contributed to this. This
thrombocytopaenia resolved with corticosteroid therapy. Overall,
there was no evidence of cumulative myelosuppression with
repeated dosing.
Non-haematological toxicity
The most frequent drug-related non-haematological toxicities,
occurring in X25% of patients, are shown in Table 5. These
comprised fatigue in 75% of patients, nausea in 58% and diarrhoea
and vomiting in 46% of patients. Thirty-three per cent of patients
experienced alopaecia and 25% dysgeusia. Constipation, cough
and headache were seen in 17% of patients, each generally at
grades 1–2 only (with 1 patient at dose level þ1 experiencing
grade 3 constipation). Peripheral neuropathy was mild and
infrequent, being reported at grade 1 in five patients (two at dose
level þ1, one at dose level A and two at dose level A1) and grade 2
in two patients only (one each at dose levels 0 and A1). Mucositis
was not reported. Overall, all toxicities were manageable, and there
were no treatment-related deaths.
Pharmacokinetics
Plasma concentrations from PK sampling were compared to
plasma concentrations from phase I studies of ispinesib. A
population PK analysis was conducted using NONMEM (Globo-
max LLC, Hanover, MD, USA) on phase I ispinesib data following
an 18mgm
 2 dose, the MTD from a once every 21-day schedule
(Chu et al, 2004). Using a validated population model, observed
ispinesib concentration–time data from this study were overlaid
on the simulated profile. Observed docetaxel data from subjects in
this study administered 60 and 75mgm
 2 were overlaid with
historical data from subjects dosed with 35, 75 and 100mgm
 2
docetaxel (Baker et al, 2003) to ascertain if an interaction was
observed affecting docetaxel concentration–time profiles.
Using this model, ispinesib plasma concentrations in cycle 1
were consistent with those observed in phase I studies, as shown in
Figure 1. Docetaxel PK parameters were consistent with those
reported historically despite the co-administration of ispinesib
(Figure 2; Baker et al, 2003).
Table 4 Summary of drug-related haematological toxicities (all cycles)
Toxicity Grade 8/60
a 8/75
a 10/60
a 12/60
a Total (%)
Anaemia 1–2 — 3 2 1 6 (25)
3–4 — — 1 2 3 (13)
Neutropaenia 1–2 1 — 1 — 2 (8)
3–4 4 5 4 5 18 (75)
Febrile neutropaenia 1–2 — — — — 0 (0)
3–4 — 2 — 2 4 (17)
Leukopaenia 1–2 — 1 1 (4)
3–4 2 3 1 1 7 (29)
Thrombocytopaenia 1–2 — — 2 2 (8)
3–4 — — — 1 1 (4)
aDose ispinesib/dose docetaxel (mgm
 2).
Table 5 Summary of drug-related non-haematological toxicities in
X25% of patients
Toxicity Grade 8/60
a 8/75
a 10/60
a 12/60
a Total (%)
Lethargy/fatigue 1–2 4 5 5 3 17 (71)
3–4 0 0 1 0 1 (4)
Nausea 1–2 3 0 5 5 13 (54)
3–4 0 0 0 1 1 (4)
Vomiting 1–2 3 1 3 3 10 (42)
3–4 0 0 0 1 1 (4)
Diarrhoea 1–2 1 1 4 2 8 (33)
3–4 1 1 0 1 3 (13)
Alopaecia 1–2 2 2 2 2 8 (33)
3–4 0 0 0 0
Dysgeusia 1–2 1 1 2 2 6 (25)
3–4 0 0 0 0
aDose ispinesib/dose docetaxel (mgm
 2).
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 2. Simulation of ispinesib concentrations based on population PK
model developed from data collected in a single agent, first in human study
of ispinesib in which subjects were dosed from 1–21mgm
 2.
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There were no confirmed complete or partial responses. A total of
seven patients had a best response of stable disease (SD) lasting
X18 weeks (six HRPC and one renal cell cancer), including one
patient with HRPC demonstrating SD for X24 weeks. Of the
patients with HRPC, one demonstrated a confirmed 450%
decrease in the serum level of prostatic-specific antigen (PSA).
DISCUSSION
Antimitotic agents targeting tubulin, including the vinca alkaloids
and taxanes, are arguably the most successful anticancer drugs
developed to date. These findings have fuelled the development of
novel antimitotics to improve drug disposition, decrease toxicity
or improve efficacy. Recent drug discovery strategies have focused
on the development of targeted agents that block the function of
key enzymes involved in mitosis, such as the aurora kinases, polo-
like kinase-1 (PLK-1) and the kinesins CENP-E and KSP (Blagden
and de Bono, 2005; Jackson et al, 2007). These agents have shown
promise in preclinical studies, and early clinical trial data indicate
that they are well tolerated at biologically active doses, with
neutropaenia being dose-limiting and showing little evidence of
neurotoxicity. This improved toxicity profile may be advanta-
geous; however, concerns remain about the basis for selective
cytotoxicity with these agents. Moreover, owing to the neutropae-
nia associated with these drugs, combining these agents with
established cytotoxics at recommended doses may be difficult.
In this phase I dose escalation study, ispinesib was combined
with docetaxel. The drugs were administered consecutively on day
1 of a 21-day schedule and 24 patients were treated. No evidence of
a drug–drug PK interaction was observed. The MTD for this study
was defined as 10mgm
 2 of ispinesib and 60mgm
 2 of docetaxel.
The tolerability profile was predictable, acceptable and manage-
able, with neutropaenia and leukopaenia occurring at a similar
frequency to that seen with single agent docetaxel (Taxotere
s,
2005). There was also sparing of the other haematopoietic lineages,
which was also evident in phase I single agent studies of ispinesib
(Chu et al, 2003, 2004; Burris et al, 2004). Peripheral neurotoxicity
was generally mild and rarely seen, with grade 2 neuropathy
observed in two patients receiving this regimen, supporting
evidence that this novel targeted antimitotic is not by itself
neurotoxic. Nonetheless, the cumulative overall administered dose
of docetaxel in this study was low and may also partly explain the
low rate of significant neurotoxicity.
The toxicity profile observed in this study was similar to that
observed in preliminary reports of other phase I studies combining
ispinesib with cytotoxic agents (Jones et al, 2006; Rodon et al,
2006). Rodon et al (2006) reported a DLT of grade 4 neutropaenia
when ispinesib and capecitabine were administered on day 1 and
days 1–14, respectively, of a 21-day schedule. However, Jones et al
(2006) reported a DLT of grade 4 neutropaenia when ispinesib was
combined with carboplatin on a day 1 every 21-day schedule.
The best objective tumour response observed was disease
stabilisation lasting X18 weeks in seven patients – six with HRPC
and one with renal cell cancer. However, in this study, just one
patient with HRPC demonstrated a confirmed X50% decline in
PSA (Bubley et al, 1999). This low PSA 50% decline rate in
advanced HRPC patients may be attributed to the suboptimal dose
of docetaxel administered, but it appears to suggest that KSP
blockade does not increase the antitumour activity at the dose
levels and schedule evaluated in this study.
Second generation KSP inhibitors are now in the clinic (Holen
et al, 2006; Stein et al, 2006). SB-743921 is five-fold more potent
than ispinesib against the ATPase activity of KSP and demon-
strates cytotoxic activity at o2n M in a range of tumour cell lines
(Jackson et al, 2006). It has been tested in 44 solid cancer patients
in a phase I study as a 1h infusion administered every 21 days
(Holen et al, 2006). The MTD has been defined as 4mgm
 2.
MK-0731 has demonstrated an IC50 of 2.2nM in several tumour cell
lines and has been administered as a 24h infusion every 21 days in
eight patients so far (Stein et al, 2006). The MTD was exceeded at
48mgm
 2 and the recommended phase II dose is being explored.
The preliminary reports of these two agents have shown a similar
toxicity profile to ispinesib with DLTs of prolonged neutropaenia
(Holen et al, 2006; Stein et al, 2006). The non-haematological
toxicity profile of MK-0731 was similar to that of ispinesib with
respect to gastrointestinal and constitutional toxicities; however, in
contrast to our study and those of single agent ispinesib, mucositis,
nail changes and phlebitis were reported (Stein et al, 2006). In
addition, transaminitis, hyperbilirubinaemia and hypophospha-
taemia were reported with SB-743921 (Holen et al, 2006).
In conclusion, this study demonstrated that docetaxel can be
safely administered with a KSP inhibitor but that non-cumulative
neutropaenia limits the dosing of both these agents. Careful
consideration needs to be given now to optimise the evaluation of
the mitotic kinesin inhibitors through rational drug combinations
that can lead to selective tumour cytotoxicity.
REFERENCES
Baker SD, Zhao M, Lee CKK, Verweij J, Zabelina Y, Brahmer JR,
Wolff AC, Sparreboom A, Carducci MA (2003) Comparative Pharmaco-
kinetics of weekly and every three weeks docetaxel. Clin Cancer Res 10:
1976–1983
Blagden S, de Bono J (2005) Drugging cell cycle kinases in cancer therapy.
Curr Drug Targets 6: 325–335
Blangy A, Lane HA, d’Herin P, Harper M, Kress M, Nigg EA (1995)
Phosphorylation by p34cdc2 regulates spindle association of human Eg5,
a kinesin-related motor essential for bipolar spindle formation in vivo.
Cell 83: 1159–1169
Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M,
Figg WD, Freidlin B, Halabi S, Hudes G, Hussain M, Kaplan R, Myers C,
Time (h)
D
o
c
e
t
a
x
e
l
 
c
o
n
c
e
n
t
r
a
t
i
o
n
 
(

g
 
m
l
−
1
)
0 5 10 15 20 25
0.001
0.010
0.100
1.000
Historical docetaxel profile 35 mg m−2
Historical docetaxel profile 75 mg m−2
Historical docetaxel profile 100 mg m−2
Observed docetaxel 60 mg m−2O
Observed docetaxel 75 mg m−2∆
Figure 2 Observed and historical docetaxel concentration time profiles.
Graph showing concentration time profiles of docetaxel for patients in this
study (at 60 and 75mgm
 2) compared to historical controls (at 35, 75 and
100mgm
 2).
Phase I trial of ispinesib and docetaxel
SP Blagden et al
898
British Journal of Cancer (2008) 98(5), 894–899 & 2008 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sOh W, Petrylak DP, Reed E, Roth B, Sartor O, Scher H, Simons J,
Sinibaldi V, Small EJ, Smith MR, Trump DL, Vollmer R, Wilding G
(1999) Eligibility and response guidelines for phase II clinical trials in
androgen-independent prostate cancer: recommendations from the
Prostate-Specific Antigen Working Group. J Clin Oncol 17: 3461–3467
Burris HA, Lorusso P, Jones S, Guthrie TM, Orr JB, Williams DD, Hodge JP,
Bush M, Sabry J (2004) Phase I trial of novel kinesin spindle protein
(KSP) inhibitor SB-715992 IV days 1, 8 15 q 28 days. Proc Am Soc Clin
Oncol 22: 14S
Chan S, Friedrichs K, Noel D, Pinte ´r T, Van Belle S, Vorobiof D, Duarte R,
Gil MG, Bodrogi I, Murray E, Yelle L, von Minckwitz G, Korec S,
Simmonds P, Buzz Fi, Gonza ´lez-Mancha R, Richardson G, Walpole E,
Ronzoni M, Murawsky M, Alakl M, Riva A, Crown J (1999) Prospective
randomized trial of docetaxel versus doxorubicin in patients with
metastatic breast cancer. J Clin Oncol 17: 2341–2354
Chu Q, Holen KD, Rowinsky EK, Wilding G, Volkman JL, Orr JB, Williams
DD, Hodge JP, Sabry J (2004) A Phase I trial of novel kinesin spindle
protein (KSP) inhibitor SB-715992 IV q 21 days. Proc Amer Soc Clin
Oncol 22: 2078
Chu QS, Holen KD, Rowinsky EK, Alberti DB, Monroe P, Volkman JL,
Hodge JP, Sabry J, Ho PTC, Wilding G (2003) A phase I study to
determine the safety and pharmacokinetics of IV administered SB-
715992, a novel kinesin spindle protein (KSP) inhibitor in patients with
solid tumors. Proc Am Soc Clin Oncol 22: 525
Cochran JC, Gatial III JE, Kapoor TM, Gilbert SP (2005) Monastrol
inhibition of the mitotic kinesin Eg5. J Biol Chem 280: 12658–12667
Drinka PJ, Langer E (1989) The Cockroft–Gault formula. J Am Geriatr Soc
37: 820
Eisenhauer EA, Vermorken JB (1998) The taxoids: comparative clinical
pharmacology and therapeutic potential. Drugs 55: 5–30
Fossella F, Pereira JR, von Pawel J, Pluzanska A, Gorbounova V, Kaukel E,
Mattson KV, Ramlau R, Szczesna A, Fidias P, Millward M, Belani CP
(2003) Randomized, multinational, phase III study of docetaxel plus
platinum combinations versus vinorelbine plus cisplatin for advanced
non-small-cell lung cancer: the TAX 326 Study Group. J Clin Oncol 21:
3016–3024
Fossella FV, DeVore R, Kerr RN, Crawford J, Natale RR, Dunphy F,
Kalman L, Miller V, Lee JS, Moore M, Gandara D, Karp D, Vokes E, Kris
M, Kim Y, Gamza F, Hammershaimb L (2000) Randomized phase III trial
of docetaxel versus vinorelbine or ifosfamide in patients with advanced
non-small-cell lung cancer previously treated with platinum-containing
chemotherapy regimens. J Clin Oncol 18: 2354–2362
Hegde PS, Cogswell J, Carrick K, Jackson J, Wood KW, Eng WK,
Brawner M, Huang PS, Bergsma D (2003) Differential gene expression
analysis of kinesin spindle protein in human solid tumors. Proc Am Soc
Clin Oncol 22: 535
Holen KD, Belani CP, Wilding G, Ramalingam S, Heideman JL,
Ramanathan RK, Bowen CJ, Williams DD, Hodge JP, Dar MM (2006)
Phase I study to determine tolerability and pharmacokinetics (PK) of SB-
743921, a novel kinesin spindle protein (KSP) inhibitor. Proc Am Soc Clin
Oncol 24: 2000
Jackson JR, Gilmartin A, Dhanak D, Gilmartin A, Dhanak D, Knight S,
Parrish C, Luo L, Sutton D, Caulder E, Diamond M, Giardiniere M, Zhang
SY, Huang P, Bergnes G, McDonald A, Lee Y, Sakowicz R, Wood KW
(2006) A second generation KSP inhibitor, SB-743921, is a highly potent
and active therapeutic in preclinical models of cancer. Proc Am Assoc
Cancer Res 2006: B11
Jackson JR, Patrick DR, Dar MM, Huang PS (2007) Targeted anti-mitotic
therapies: can we improve on tubulin agents? Nat Rev Canc 7: 107–117
Johnson RK, McCabe FL, Cauder E, Inlow-Porter L, Whitacre M,
Winkler JD, Bergnes G, Feng B, Morgans D, Wood KW, Jackson JR
(2002) SB-715992, a potent and selective inhibitor of KSP mitotic kinesin,
demonstrates broad-spectrum activity in advanced murine tumors and
human tumor xenografts. Proc Am Assoc Cancer Res 43: 269
Jones SF, Plummer ER, Burris HA, Razak AR, Meluch AA, Bowen CJ,
Williams DH, Hodge JP, Dar MM, Calvert AH (2006) Phase I study of
ispinesib in combination with carboplatin in patients with advanced
solid tumors. Proc Am Soc Clin Oncol 24: 2027; 18S
Mayer TU, Kapoor TM, Haggarty SJ, King RW, Schreiber SL, Mitchison T
(1999) Small molecule inhibitor of mitotic spindle bipolarity identified in
a phenotype-based screen. Science 286: 971–974
Miller K, Ng C, Ang P, Brufsky AM, Lee SC, Dees EC, Piccart M, Verrill M,
Wardley A, Loftiss J, Bal J, Yeoh S, Hodge J, Williams D, Dar M, Ho PTC
(2005) Phase II, Open Label Study of Ispinesib in Patients with Locally
Advanced or Metastatic Breast Cancer. San Antonio Breast Cancer
Symposium 2005: 1089
Nabholtz J-M, Senn HJ, Bezwoda WR, Melnychuk D, Desche ˆnes L,
Douma J, Vandenberg TA, Rapoport B, Rosso R, Trillet-Lenoir V,
Drbal J, Molino A, Nortier JWR, Richel DJ, Nagykalnai T, Siedlecki P,
Wilking N, Genot JY, Hupperets PSGJ, Pannuti F, Skarlos D, Tomiak EM,
Murawsky A, Alakl M, Riva A, Aapro M (1999) Prospective randomized
trial of docetaxel versus mitomycin plus vinblastine in patients with
metastatic breast cancer progressing despite previous anthracycline-
containing chemotherapy. J Clin Oncol 17: 1413–1424
Rodon J, Till E, Patnaik A, Takimoto C, Beeram M, Williams D, Bowen C,
Hodge J, Dar M, Tolcher A (2006) Phase I study of ispinesib (SB-715992),
a kinesin spindle protein inhibitor, in combination with capecitabine in
patients with advanced solid tumors. Eur J Canc Suppl 4: 193
Sakowicz R, Finer JT, Beraud C, Crompton A, Lewis E, Fritsch A, Lee Y,
Mak J, Moody R, Turincio R, Chabala JC, Gonzales P, Roth S, Weitman S,
Wood KW (2004) Antitumor activity of a kinesin inhibitor. Cancer Res
64: 3276–3280
Shahin M, Braly P, Rose P, Malpass T, Bailey H, Alvarez RD, Hodge J,
Bowen C, Buller R (2007) A phase II, open-label study of ispinesib (SB-
715992) in patients with platinum/taxane refractory or resistant relapsed
ovarian cancer. Proc Am Soc Clin Oncol 21: 5562
Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O’Rourke M,
Levitan N, Gressot L, Vincent M, Burkes R, Coughlin S, Kim Y,
Berille J (2000) Prospective randomized trial of docetaxel versus
best supportive care in patients with non-small-cell lung cancer
previously treated with platinum-based chemotherapy. J Clin Oncol 18:
2095–2103
Stein MN, Rubin EH, Scott PD, Fernandez R, Agrawal NG, Hsu K,
Walker A, Holen K, Wilding G (2006) Phase I clinical and pharmaco-
kinetic (PK) trial of the kinesin spindle protein (KSP) inhibitor MK-0731
in cancer patients. Proc Am Soc Clin Oncol 24: 2001
Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S,
The ´odore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA
(2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for
advanced prostate cancer. N Engl J Med 351: 1502–1512
Taxotere
s Prescribing Information (2005). Bridgewater, NJ: Aventis
Pharmaceuticals Inc.
Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS,
Rubinstein L, Verweij J, van Glabbeke M, van Oosterom AT, Christian
MC, Gwyther SG (2000) New guidelines to evaluate the response to
treatment in solid tumors. J Natl Cancer Inst 92: 205–216
Wood KW, Cornwell WD, Jackson JR (2001) Past and future of the mitotic
spindle as an oncology target. Curr Opin Pharmacol 1: 370–377
Phase I trial of ispinesib and docetaxel
SP Blagden et al
899
British Journal of Cancer (2008) 98(5), 894–899 & 2008 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
s